{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"description":"Percentage of donors from whom at least 2 x 10\\^6 CD34+ cells/kg body weight were collected based on actual recipient body weight","groups":[{"description":"Donors receive filgrastim subcutaneously (SC) and plerixafor SC on day -14 and undergo leukapheresis to collect peripheral blood stem cells (PBSC) on day -13. These cells are frozen to preserve them. Treatment modifications may apply according to sufficient collection of PBSC. Patients receive standard high-dose conditioning and undergo allogeneic PBSC transplantation on day 0 using the previously frozen cells.\n\nAfter completion of study treatment, donors are followed up 1 day after the last stem cell donation.\n\nplerixafor: Given SC\n\nfilgrastim: Given SC\n\nperipheral blood stem cell transplantation: Infusion of peripheral blood stem cells\n\nallogeneic hematopoietic stem cell transplantation: Infusion of hematopoietic stem cells","id":"OG000","title":"Filgrastim and Plerixafor for PBSC Mobilization"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Study terminated early. Results are for the one donor enrolled.","reportingStatus":"POSTED","timeFrame":"At the end of apheresis for cell collection","title":"Successful Collection of Stem Cells","type":"PRIMARY","unitOfMeasure":"Participants"}